RS51852B - Modifikovani peptidi kao terapeutski agensi - Google Patents

Modifikovani peptidi kao terapeutski agensi

Info

Publication number
RS51852B
RS51852B YU25901A YUP25901A RS51852B RS 51852 B RS51852 B RS 51852B YU 25901 A YU25901 A YU 25901A YU P25901 A YUP25901 A YU P25901A RS 51852 B RS51852 B RS 51852B
Authority
RS
Serbia
Prior art keywords
peptide
seq
peptides
composition
sequence
Prior art date
Application number
YU25901A
Other languages
English (en)
Serbian (sr)
Inventor
Ulrich Feige
Chuan-Fa Liu
Janet Cheetham
Thomas Charles Boone
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26802505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51852(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of YU25901A publication Critical patent/YU25901A/sh
Publication of RS51852B publication Critical patent/RS51852B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
YU25901A 1998-10-23 1999-10-25 Modifikovani peptidi kao terapeutski agensi RS51852B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10537198P 1998-10-23 1998-10-23
US09/428,082 US6660843B1 (en) 1998-10-23 1999-10-22 Modified peptides as therapeutic agents

Publications (2)

Publication Number Publication Date
YU25901A YU25901A (sh) 2005-07-19
RS51852B true RS51852B (sr) 2012-02-29

Family

ID=26802505

Family Applications (1)

Application Number Title Priority Date Filing Date
YU25901A RS51852B (sr) 1998-10-23 1999-10-25 Modifikovani peptidi kao terapeutski agensi

Country Status (29)

Country Link
US (7) US6660843B1 (https=)
EP (1) EP1144454B2 (https=)
JP (9) JP2003512011A (https=)
KR (3) KR100753305B1 (https=)
CN (8) CN100384880C (https=)
AT (1) ATE380828T1 (https=)
AU (3) AU767725B2 (https=)
BG (1) BG65721B1 (https=)
BR (1) BR9914708A (https=)
CA (1) CA2347131C (https=)
CY (1) CY1107881T1 (https=)
CZ (1) CZ304242B6 (https=)
DE (1) DE69937752T3 (https=)
DK (1) DK1144454T4 (https=)
EA (1) EA005404B1 (https=)
ES (1) ES2299278T5 (https=)
HK (1) HK1042097B (https=)
HU (1) HU229485B1 (https=)
IL (2) IL142365A0 (https=)
MX (1) MXPA01003873A (https=)
NO (1) NO331733B1 (https=)
NZ (2) NZ528882A (https=)
PL (1) PL211164B1 (https=)
PT (1) PT1144454E (https=)
RS (1) RS51852B (https=)
SI (1) SI1144454T2 (https=)
SK (1) SK287037B6 (https=)
WO (1) WO2000024782A2 (https=)
ZA (1) ZA200102753B (https=)

Families Citing this family (575)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743777B1 (en) * 1992-03-19 2004-06-01 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
MEP42108A (en) * 1998-10-23 2011-02-10 Kiren Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
WO2000047740A2 (en) * 1999-02-12 2000-08-17 Amgen Inc. Tnf-related proteins
KR20020003864A (ko) * 1999-03-03 2002-01-15 피터 지. 스트링거 에키노칸딘/탄수화물 착물
EP1582204B1 (en) * 1999-03-03 2013-09-25 Eli Lilly & Company Echinocandin pharmaceutical formulations containing micelle-forming surfactants
AU779612C (en) 1999-07-02 2005-12-15 Genentech Inc. Peptide compounds that bind HER2
IL147269A0 (en) 1999-07-02 2002-08-14 Genentech Inc FVIIa ANTAGONISTS
US7754855B1 (en) * 1999-07-13 2010-07-13 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001009165A2 (en) * 1999-07-29 2001-02-08 The Johns Hopkins University ACTIVATION OF PEPTIDE PRODRUGS BY hK2
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6808902B1 (en) * 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
DE60117781T2 (de) 2000-04-21 2006-11-23 Amgen Inc., Thousand Oaks Peptidderivate des apolipoproteins-a1/aii
AU5943201A (en) * 2000-05-03 2001-11-12 Amgen Inc Modified peptides as therapeutic agents
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
WO2001087977A2 (en) * 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
CN1318084C (zh) * 2000-05-26 2007-05-30 奥索-麦克尼尔药品公司 神经保护肽
MXPA02011891A (es) * 2000-06-02 2004-04-02 Eidgenoess Tech Hochschule Reacciones de adicion conjugadas para la entrega controlada de compuestos farmaceuticamente activos.
US7355019B2 (en) * 2000-06-06 2008-04-08 Sibtech, Inc. Cysteine-containing peptide tag for site-specific conjugation of proteins
CA2421588C (en) * 2000-09-05 2010-01-26 Amgen Inc. Tnf receptor-like molecules and uses thereof
AU2003295623B2 (en) * 2000-12-05 2008-06-05 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
ATE320450T1 (de) * 2000-12-05 2006-04-15 Alexion Pharma Inc Rationell entworfene antikörper
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7622446B2 (en) * 2001-04-18 2009-11-24 The Open University Polypeptides, derivatives and uses thereof
US7491702B2 (en) * 2001-04-18 2009-02-17 The Open University Polypeptides related to amyloid precursor protein, pharmaceutical compositions thereof, and methods of treatment using the same
DK1385882T3 (da) 2001-05-11 2008-02-11 Amgen Inc Peptider og relaterede molekyler, der binder til TALL-1
EP2295081B1 (en) * 2001-06-26 2018-10-31 Amgen Inc. Antibodies to OPGL
DE60232742D1 (de) 2001-10-04 2009-08-06 Immunex Corp Ul16-bindungsprotein 4
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US20030113270A1 (en) * 2001-12-14 2003-06-19 Clark Abbot F. Vasoactive intestinal peptides for glaucomatous retinopathy
US20030138975A1 (en) * 2001-12-20 2003-07-24 Kimberly-Clark Worldwide, Inc. Diagnostic signal amplification with proteinoid microspheres
US7056535B2 (en) * 2001-12-20 2006-06-06 Kimberly-Clark Worldwide, Inc. Triggered release from proteinoid microspheres
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
CA2480121C (en) 2002-03-27 2012-02-28 Immunex Corporation Methods for increasing polypeptide production
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US7718776B2 (en) 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US6991800B2 (en) * 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
CA2490409A1 (en) * 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
EP1527096A2 (en) * 2002-08-06 2005-05-04 AplaGen GmbH Binding molecules
DE50212514D1 (de) * 2002-08-06 2008-08-28 Aplagen Gmbh Synthetische Mimetika von physiologischen Bindungsmolekülen
JP2006508056A (ja) 2002-08-28 2006-03-09 イミュネックス・コーポレーション 心臓血管疾患を治療するための組成物および方法
KR101317045B1 (ko) 2002-09-06 2013-10-16 암젠 인코포레이티드 치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
BR0314227A (pt) * 2002-09-11 2005-10-25 Fresenius Kabi De Gmbh Derivados de amido de hidroxialquila
ES2781475T3 (es) 2002-09-18 2020-09-02 Janssen Pharmaceuticals Inc Métodos para aumentar la producción de células madre hematopoyéticas y plaquetas
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
US20040149235A1 (en) * 2002-10-04 2004-08-05 Pogue Albert S. Apparatus and method for removal of waste from animal production facilities
PT1558643E (pt) * 2002-11-09 2009-08-24 Immunocore Ltd Apresentação de um receptor das células t
BR0317538A (pt) * 2002-12-20 2005-11-29 Amgen Inc Agente ligante, sequência de polinucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos de inibir a atividade de miostatina, de aumentar a massa muscular magra e a razão de massa muscular magra para gordura, de tratar uma doença de emaciação muscular e um distúrbio metabólico relacionado com miostatina em um indivìduo, de detectar e medir miostatina em uma amostra, e, de diagnosticar um distúrbio relacionado com miostatina em um indivìduo
US7125849B2 (en) * 2003-01-14 2006-10-24 The Scripps Research Institute Peptide-based angiogenesis inhibitors and methods of use thereof
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
DE502004007051D1 (de) * 2003-02-06 2008-06-19 Merck Patent Gmbh Peptidische sulfonamide
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
WO2004108885A2 (en) * 2003-05-06 2004-12-16 Syntonix Pharmaceuticals, Inc. Fc chimeric proteins with anti-hiv drugs
AU2004238263A1 (en) * 2003-05-06 2004-11-25 Syntonix Pharmaceuticals, Inc. Inhibition of drug binding to serum albumin
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
PL2298347T3 (pl) * 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
AU2004238868B2 (en) * 2003-05-12 2010-01-21 Affymax, Inc. Peptides that bind to the erythropoietin receptor
US7919118B2 (en) * 2003-05-12 2011-04-05 Affymax, Inc. Spacer moiety for poly (ethylene glycol) modified peptide based compounds
CN1820024B (zh) * 2003-05-12 2011-06-22 阿费麦克斯公司 新的聚(乙二醇)修饰的化合物及其用途
ATE428727T1 (de) 2003-05-12 2009-05-15 Affymax Inc Neue, an den erythropoietinrezeptor bindende peptide
EP1638995B1 (de) * 2003-06-20 2015-08-26 Siemens Healthcare Diagnostics Products GmbH Neue oberflächenprotein-(hbsag-) variante des hepatitis b virus
TWI476206B (zh) 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
EP2133362B1 (en) 2003-07-25 2012-04-18 Amgen, Inc Methods relating to LDCAM and CRTAM
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
EP1668114B1 (en) * 2003-08-18 2009-11-04 The Regents of the University of California Polypeptide display libraries and methods of making and using thereof
ES2304069B1 (es) * 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
US8158589B2 (en) 2003-08-22 2012-04-17 Proyecto Biomedicine Cima, S.L. Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
UA89481C2 (uk) * 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
EP1687452A4 (en) * 2003-09-30 2008-08-06 Centocor Inc HUMAN HINGE-CORE MIMETICORPS, COMPOSITIONS, METHODS AND APPLICATIONS THEREOF
AU2004287431B2 (en) 2003-10-27 2010-03-11 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
ES2383300T3 (es) 2003-11-13 2012-06-20 Hanmi Holdings Co., Ltd Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
EP1691763A4 (en) 2003-12-12 2008-03-12 Genencor Int MOLECULES CAB
US20070249530A1 (en) * 2004-01-29 2007-10-25 Genentech, Inc. Bcma Polypeptides and Uses Thereof
ES2390885T3 (es) * 2004-03-11 2012-11-19 Fresenius Kabi Deutschland Gmbh Conjugados de hidroxialquilalmidón y una proteína
JP5191729B2 (ja) 2004-03-11 2013-05-08 フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 還元的アミノ化によって製造される、ヒドロキシアルキルデンプンとタンパク質とのコンジュゲート
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
RS57852B1 (sr) * 2004-04-02 2018-12-31 Swedish Orphan Biovitrum Ab Publ Postupci za smanjenje agregacije il-1ra
US20050222040A1 (en) * 2004-04-05 2005-10-06 Blm Group, Inc. Vertebrate peptide modulators of lipid metabolism
EP1735350B1 (en) 2004-04-15 2010-08-25 Genencor International, Inc. Anti-cea scfv - beta-lactamase constructs (cab molecules) in adept
JP2005309295A (ja) * 2004-04-26 2005-11-04 Nec Corp 光増幅素子、光増幅装置および光増幅システム
US7608579B2 (en) * 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US20050281798A1 (en) * 2004-06-16 2005-12-22 Glen Gong Targeting sites of damaged lung tissue using composition
US20050281739A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue using compositions
US7553810B2 (en) * 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US7468350B2 (en) 2004-06-16 2008-12-23 Pneumrx, Inc. Glue composition for lung volume reduction
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
CA2571292C (en) * 2004-06-30 2013-05-21 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
CA2570261C (en) 2004-07-08 2014-06-10 Pneumrx, Inc. Pleural effusion treatment device, method and material
US8143380B2 (en) * 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US8080245B2 (en) * 2004-08-04 2011-12-20 University Of Massachusetts Anti-pathogen immunoadhesins
US20060210542A1 (en) * 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
WO2006036834A2 (en) * 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
WO2006036922A2 (en) * 2004-09-27 2006-04-06 Centocor, Inc. Srage mimetibody, compositions, methods and uses
AU2005305182A1 (en) * 2004-11-04 2006-05-18 Genentech, Inc. Polypeptides that bind BAFF and/or APRIL
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
JP2008519858A (ja) * 2004-11-11 2008-06-12 アフィーマックス・インコーポレイテッド エリスロポエチンレセプターに結合する新規ペプチド
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20070110760A1 (en) * 2005-01-14 2007-05-17 Monroe John G Methods and compositions targeting viral and cellular ITAM motifs, and use of same in identifying compounds with therapeutic activity
US8053415B2 (en) * 2005-01-21 2011-11-08 Washington University In St. Louis Compounds having RD targeting motifs
EP2382996B1 (en) * 2005-02-18 2015-01-14 The University of Tokushima Lipid film structure containing a polyoxyalkylene chain-containing lipid derivative.
US7723472B2 (en) * 2005-02-28 2010-05-25 The Regents Of The University Of California Extracellular matrix binding chimeric proteins and methods of use thereof
US20060241040A1 (en) * 2005-04-06 2006-10-26 Alberto Visintin Methods of treating disorders associated with toll-like receptor 4 (TLR4) signalling
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US8101728B2 (en) 2005-04-28 2012-01-24 Danisco Us Inc. TAB molecules
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
US7566456B2 (en) * 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
WO2006136450A2 (en) * 2005-06-23 2006-12-28 Aplagen Gmbh Supravalent compounds
CN103145842A (zh) * 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
EP2397498A3 (en) 2005-07-18 2013-11-27 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
RU2423381C2 (ru) * 2005-07-25 2011-07-10 Трабьон Фармасьютикалз, Инк. Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
RU2428430C2 (ru) * 2005-08-16 2011-09-10 Ханми Холдингс Ко., Лтд. СПОСОБ МАССОВОГО ПРОИЗВОДСТВА ОБЛАСТИ Fc ИММУНОГЛОБУЛИНА С УДАЛЕННЫМИ НАЧАЛЬНЫМИ МЕТИОНИНОВЫМИ ОСТАТКАМИ
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
KR100780405B1 (ko) * 2005-08-31 2007-11-28 재단법인서울대학교산학협력재단 알파 나선형 펩티드를 이용한 ｒｎａ 특이적 결합 펩티드탐색 방법
AU2006284651C1 (en) 2005-08-31 2013-09-12 The Regents Of The University Of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
EP1762250A1 (en) * 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
WO2007041317A2 (en) * 2005-09-29 2007-04-12 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
EP1928905B1 (de) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
WO2007044616A2 (en) 2005-10-06 2007-04-19 Xencor, Inc. Optimized anti-cd30 antibodies
US8445642B1 (en) * 2005-10-13 2013-05-21 The United States Of America As Represented By The Secretary Of Agriculture Methods to differentiate protein conformers
WO2007142667A2 (en) 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
EA200801174A1 (ru) * 2005-10-24 2009-02-27 Сентокор, Инк. Антитела-миметики glp-2, полипептиды, композиции, способы и применения
US7723477B2 (en) * 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CA2628221A1 (en) * 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Anti-frizzled receptor antibodies for treating cancer
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
WO2007067616A2 (en) * 2005-12-06 2007-06-14 Amgen Inc Uses of myostatin antagonists
WO2007067564A2 (en) 2005-12-08 2007-06-14 Amgen Inc. Improved host cells and culture methods
MY155286A (en) 2005-12-12 2015-09-30 Hoffmann La Roche Antibodies against amyloid beta 4 with glycosylated in the variable region
US20090054763A1 (en) * 2006-01-19 2009-02-26 The Regents Of The University Of Michigan System and method for spectroscopic photoacoustic tomography
WO2007102946A2 (en) * 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
EP1991577A2 (en) 2006-01-31 2008-11-19 Parkinson, John F. Modulation of mdl-1 activity for treatment of inflammatory disease
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
DK2005185T3 (da) 2006-03-22 2011-01-31 Viral Logic Systems Technology Corp Fremgangsmåde til identifikation af polypeptidtargets
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
US20100034819A1 (en) * 2006-03-31 2010-02-11 Centocor Inc. Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions on renal disease associated anemia
CA2647524C (en) 2006-04-05 2019-11-26 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
DE602007007923D1 (de) * 2006-04-11 2010-09-02 Csl Behring Gmbh Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
JP2009537145A (ja) * 2006-05-15 2009-10-29 バイラル ロジック システムズ テクノロジー コーポレーション 免疫学的疾患および障害を治療するためのｃｄ４７と関連した組成物および方法
NZ573646A (en) * 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
US20080096900A1 (en) 2006-06-26 2008-04-24 Amgen Inc. Methods for treating atherosclerosis
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
AU2007292242A1 (en) * 2006-09-08 2008-03-13 Genentech, Inc. Wnt antagonists and their use in the diagnosis and treatment of Wnt-mediated disorders
WO2008033333A2 (en) 2006-09-08 2008-03-20 Amgen Inc. Il-1 family variants
JP2010502224A (ja) * 2006-09-08 2010-01-28 アボット・ラボラトリーズ インターロイキン１３結合タンパク質
US20140147441A1 (en) * 2006-09-12 2014-05-29 The General Hospital Corporation Compositions containing alpha-1-antitrypsin and methods for use
WO2008100288A2 (en) * 2006-09-15 2008-08-21 The Burnham Institute High affinity ephb receptor binding compounds and methods of use thereof
EP2063905B1 (en) 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
WO2008036688A2 (en) 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
WO2008036763A2 (en) * 2006-09-20 2008-03-27 Pneumrx, Inc. Tissue adhesive compositions and methods thereof
US20100034194A1 (en) * 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
US20080123083A1 (en) * 2006-11-29 2008-05-29 The Regents Of The University Of Michigan System and Method for Photoacoustic Guided Diffuse Optical Imaging
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
ES2409756T3 (es) * 2006-12-04 2013-06-27 Promedior, Inc. Combinación de SAP y de enalapril para su uso en tratamiento de trastornos fibróticos o fibroproliferativos
US20100166734A1 (en) * 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides
KR100888022B1 (ko) 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
CA2673459C (en) 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
EP2118127A4 (en) 2007-01-31 2010-12-01 Affymax Inc NICKET-BASED LINKER FOR BONDING MODIFYING GROUPS OF POLYPEPTIDES AND OTHER MACROMOLECULES
CA2678001C (en) 2007-02-12 2017-07-11 Stefan Schulte Therapeutic application of kazal-type serine protease inhibitors
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
US20110159018A1 (en) 2007-05-03 2011-06-30 Medizinische Universitat Innsbruck Complement factor h-derived short consensus repeat-antibody constructs
EP2158318A2 (en) * 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
EP2162540A2 (en) 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
PE20090329A1 (es) * 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
US20100260680A1 (en) * 2007-06-05 2010-10-14 Oriental Yeast Co., Ltd. Novel bone mass increasing agent
US20090054332A1 (en) * 2007-06-21 2009-02-26 Conjuchem Biotechnologies, Inc. Thombopoietin peptide conjugates
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
BRPI0814465B1 (pt) 2007-07-26 2021-11-23 Novagen Holding Corporation Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica
US8293685B2 (en) 2007-07-26 2012-10-23 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
HRP20140315T1 (hr) 2007-07-26 2014-05-09 Amgen Inc. Modificirani enzimi lecitin-kolesterol aciltransferaze
TW200911289A (en) * 2007-08-09 2009-03-16 Syntonix Pharmaceuticals Inc Immunomodulatory peptides
WO2009026122A1 (en) * 2007-08-17 2009-02-26 Amgen Inc. Formulations of antibodies and fc-fusion molecules using polycations
EP2615114B1 (en) 2007-08-23 2022-04-06 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2009033212A1 (en) * 2007-09-11 2009-03-19 Christopher Hovens The use of estrogen and androgen binding proteins in methods and compositions for treating gynaecological cancers
EP2205280B1 (en) 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
BRPI0817524A2 (pt) * 2007-10-02 2017-05-02 Potentia Pharmaceuticals Inc liberação prolongada de análogos de compstatina provenientes de géis
US7829735B2 (en) 2007-10-26 2010-11-09 Northwestern University Universal phosphoramidite for preparation of modified biomolecules and surfaces
US8796206B2 (en) 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
EP2235058A2 (en) 2007-12-21 2010-10-06 Amgen, Inc Anti-amyloid antibodies and uses thereof
HRP20150279T1 (hr) 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
US20140127200A1 (en) * 2008-01-03 2014-05-08 The Scripps Research Institute Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains
WO2009094551A1 (en) 2008-01-25 2009-07-30 Amgen Inc. Ferroportin antibodies and methods of use
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
CN101518644B (zh) * 2008-02-26 2011-07-13 上海交通大学医学院附属第九人民医院 Ang-2及其基因在制药中的应用
PL2257311T3 (pl) * 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
RU2531754C2 (ru) 2008-04-11 2014-10-27 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
US8293714B2 (en) * 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
EP2116556B1 (en) 2008-05-09 2016-03-23 AbbVie Deutschland GmbH & Co KG Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
US20110076723A1 (en) * 2008-05-23 2011-03-31 Samsung Electronics Co., Ltd. Antibody-peptide fused synergibody
TW201006485A (en) 2008-06-03 2010-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2726087A1 (en) 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
US8034770B2 (en) 2008-06-04 2011-10-11 Amgen Inc. FGF21 polypeptides comprising two or more mutations
PL2291523T3 (pl) 2008-06-24 2015-05-29 Csl Behring Gmbh Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
CN102149825B (zh) 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
MX2011000861A (es) * 2008-07-23 2011-06-21 Hanmi Holdings Co Ltd Un complejo polipeptidico que consiste en un polimero no-peptidil que posee tres terminaciones funcionales.
WO2010014909A1 (en) * 2008-08-01 2010-02-04 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
EP2168590A1 (en) * 2008-09-24 2010-03-31 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Antimicrobial peptides
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
JP5611222B2 (ja) 2008-11-26 2014-10-22 アムジエン・インコーポレーテツド アクチビンｉｉｂ受容体ポリペプチドの変異体及びその使用
WO2010081095A2 (en) * 2009-01-12 2010-07-15 The Regents Of The University Of California Methods and compositions for inhibiting hepatitis c virus replication
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
EP2391652A4 (en) * 2009-01-29 2013-01-02 Abbott Lab IL-1 BINDING PROTEINS
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
TWI541021B (zh) 2009-03-05 2016-07-11 艾伯維有限公司 Ｉｌ－１７結合蛋白
US8283162B2 (en) * 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof
CA2754961C (en) * 2009-03-11 2018-04-10 Promedior, Inc. Treatment and diagnostic methods for hypersensitive disorders
EP2405929B1 (en) * 2009-03-11 2018-06-06 Promedior Inc. A sap polypeptide for use in the treatment of autoimmune disorders and graft vs host disease
CA2755336C (en) 2009-03-20 2015-07-14 Amgen Inc. Carrier immunoglobulins and uses thereof
US20120018338A1 (en) 2009-03-30 2012-01-26 Hoffman-La Roche Inc. Method for avoiding glass fogging
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2010129503A1 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
CN102482324B (zh) * 2009-06-15 2014-07-02 拜欧肯疗法有限公司 能够抑制自身免疫、炎症和癌症进程的新型趋化因子结合多肽
MX2011013903A (es) 2009-06-17 2012-05-08 Amgen Inc Polipeptidos quimericos y usos de los mismos.
EP2987803B1 (en) * 2009-06-17 2018-08-29 Promedior Inc. Sap variants and their use
EP3366692A1 (en) 2009-06-22 2018-08-29 Amgen, Inc Refolding proteins using a chemically controlled redox state
AU2010266093B2 (en) 2009-06-25 2013-06-27 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
RU2012103240A (ru) 2009-07-02 2013-08-10 Ангиокем Инк. Мультимерные пептидные конъюгаты и их применение
IT1395137B1 (it) * 2009-08-05 2012-09-05 Spider Biotech S R L Nuovi peptidi antipatogeni
BR112012004546A8 (pt) 2009-08-29 2017-12-05 Abbott Lab Terapêutica por proteínas ligantes dll4-ligantes
WO2011028811A2 (en) 2009-09-01 2011-03-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2478013B1 (en) 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Coiled coil and/or tether containing protein complexes and uses thereof
US20120183546A1 (en) 2009-09-23 2012-07-19 Amgen Inc. Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
EP2480888B1 (en) 2009-09-25 2016-11-30 XOMA Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011053707A1 (en) * 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
MX341084B (es) 2009-11-02 2016-08-05 Univ Washington Composiciones de nucleasas terapéuticas y métodos.
WO2011060242A2 (en) * 2009-11-13 2011-05-19 Talecris Biotherapeutics, Inc. Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
EP2498803A4 (en) 2009-11-13 2013-05-15 Puget Sound Blood Ct FACTOR VIII CELL EPITOPARIANTS WITH REDUCED IMMUNOGENITY
US20120231006A1 (en) 2009-11-20 2012-09-13 Amgen Inc. Anti-orai1 antigen binding proteins and uses thereof
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
MX2012006560A (es) 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
CA2785907A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
SG10201503351RA (en) 2010-01-19 2015-06-29 Harvard College Engineered Opsonin for Pathogen Detection and Treatment
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
KR101784539B1 (ko) 2010-01-28 2017-10-11 랩터 파마슈티컬스 인코포레이티드 수용체 결합 단백질(ｒａｐ) 펩타이드-푸코시다제 억제제 접합체를 이용한 간 질환의 치료방법
JP2013519699A (ja) 2010-02-16 2013-05-30 ノヴォ ノルディスク アー／エス 因子ｖｉｉｉ融合タンパク質
WO2011109415A2 (en) 2010-03-02 2011-09-09 Amgen Inc. Reducing viscosity of pharmaceutical formulations
KR101853278B1 (ko) 2010-03-02 2018-05-02 애브비 인코포레이티드 치료학적 ｄｌｌ４ 결합 단백질
JP6190113B2 (ja) 2010-03-03 2017-08-30 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア オリゴマー特異アミロイドベータエピトープおよび抗体
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
JP2013528357A (ja) 2010-03-29 2013-07-11 ザイムワークス，インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
AR081755A1 (es) 2010-04-02 2012-10-17 Hanmi Holdings Co Ltd Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo
US20130101590A1 (en) * 2010-04-09 2013-04-25 Heather A. Arnett Btnl9 proteins, nucleic acids, and antibodies and uses thereof
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
MX2012013144A (es) 2010-05-14 2012-11-30 Amgen Inc Agonistas mejorados de receptor de muerte.
AR081246A1 (es) 2010-05-14 2012-07-18 Abbott Lab Proteinas de union a il-1
CN102260343A (zh) 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 重组人g-csf二聚体在治疗神经损伤疾病中的用途
US20110305670A1 (en) * 2010-06-10 2011-12-15 President And Fellows Of Harvard College Nucleic acid encoding fusion polypeptides that prevent or inhibit hiv infection
WO2012012141A1 (en) 2010-06-30 2012-01-26 Amgen Inc. Scnn1a/tnfrsf1a fusion proteins in cancer
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
US9120862B2 (en) 2010-07-26 2015-09-01 Abbott Laboratories Antibodies relating to PIVKA-II and uses thereof
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
CA2808185A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1.beta. and il-18, for treatment of disease
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
MX360946B (es) 2010-09-22 2018-10-29 Amgen Inc Star Inmunoglobulinas portadoras y usos de las mismas.
PT2621515T (pt) 2010-09-28 2017-07-12 Aegerion Pharmaceuticals Inc Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
TW201307388A (zh) 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
PE20141060A1 (es) 2010-12-21 2014-09-26 Abbvie Inc Inmunoglobulinas de dominio variable dual biespecificas de il-1 alfa y beta y su uso
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2012097333A2 (en) 2011-01-14 2012-07-19 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
SG10201600531TA (en) 2011-01-24 2016-02-26 Univ Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
RU2018108836A (ru) 2011-02-04 2019-03-14 Дженентек, Инк. ВАРИАНТЫ Fc И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
EP2673297A2 (en) 2011-02-11 2013-12-18 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
CA2828405A1 (en) 2011-02-28 2012-09-07 Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Apoptosis-inducing molecules and uses therefor
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
US9352016B2 (en) 2011-03-09 2016-05-31 Csl Behring Gmbh Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces
PH12013501865A1 (en) 2011-03-16 2014-01-06 Amgen Inc Potent and selective inhibitors of nav1.3 and nav1.7
US8628773B2 (en) 2011-04-07 2014-01-14 Amgen Inc. Antigen binding proteins
CN103608354B (zh) * 2011-04-25 2016-10-05 大鹏药品工业株式会社 含有pH-响应肽的纳米颗粒
ES2666303T3 (es) 2011-04-29 2018-05-03 University Of Washington Composiciones terapéuticas de nucleasa y métodos
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
UA126465C2 (uk) 2011-06-10 2022-10-12 Ханмі Сайенс Ко., Лтд. Пептид, що має активність оксинтомодуліну, та фармацевтична композиція для лікування ожиріння, яка його містить
RU2607365C2 (ru) 2011-06-17 2017-01-10 Ханми Сайенс Ко., Лтд. Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение
WO2013003606A1 (en) 2011-06-29 2013-01-03 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
AU2012284097B2 (en) 2011-07-18 2017-08-03 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
WO2013012855A1 (en) 2011-07-18 2013-01-24 Amgen Inc. Apelin antigen-binding proteins and uses thereof
BR112014001274A2 (pt) 2011-07-18 2017-04-18 Arts Biologics As composto de hormônio luteinizante, e, composição farmacêutica
IL230564B2 (en) 2011-07-22 2023-09-01 Csl Ltd Anticoagulant monoclonal antibodies anti–factor xii/fxiia, a method for their preparation, a pharmaceutical compound containing them and medical uses.
CN103732240B (zh) 2011-07-25 2015-12-09 健能隆医药技术（上海）有限公司 G-csf二聚体在制备治疗神经退行性疾病药物中的应用
WO2013025479A1 (en) 2011-08-16 2013-02-21 Emory University Jaml specific binding agents, antibodies, and uses related thereto
DE102012016127A1 (de) 2011-08-31 2013-02-28 Daniel Elias Bioaktive, regenerative Mischung zur Herstellung eines Ergänzungsnahrungsmittels
AU2012301713A1 (en) * 2011-08-31 2014-03-06 Indi Molecular, Inc. VEGF-specific capture agents, compositions and methods of using and making
JP2014529473A (ja) 2011-09-02 2014-11-13 アムジエン・インコーポレーテツド 医薬製品および医薬製品の露光を分析する方法
TWI593708B (zh) 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
RU2654567C2 (ru) 2011-10-11 2018-05-21 Дженентек, Инк. Улучшенная сборка биспецифических антител
PE20141545A1 (es) 2011-10-24 2014-11-26 Abbvie Inc Inmunoenlazadores dirigidos contra el tnf
RU2014121043A (ru) 2011-10-24 2015-12-10 Эббви Инк. Биспецифические иммуносвязывающие средства, направленные против tnf и il-17
EA201992617A1 (ru) 2011-10-26 2020-03-10 Амген Инк. Способы уменьшения или устранения модификации и разложения белка, обусловленных воздействием уф-излучения
CN102516393B (zh) * 2011-11-30 2017-03-15 北京康明百奥新药研发有限公司 胰岛素模拟肽融合蛋白和突变体及其应用
CA3204283A1 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
HK1203384A1 (en) 2011-12-19 2015-12-11 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
KR102055958B1 (ko) 2011-12-22 2019-12-13 글리코미메틱스, 인크. E-셀렉틴 길항제 화합물, 조성물, 및 이용 방법
CN102558358A (zh) * 2011-12-30 2012-07-11 张海涛 人成纤维细胞生长因子21融合蛋白及其突变体的制备与应用
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
EP2806781B1 (en) 2012-01-23 2018-03-21 Washington University Goggle imaging systems and methods
EP3369746A1 (en) 2012-01-27 2018-09-05 AbbVie Deutschland GmbH & Co KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
CA2861124A1 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
WO2013120939A1 (en) 2012-02-15 2013-08-22 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
AU2013222188A1 (en) 2012-02-22 2014-09-11 Amgen Inc. Autologous mammalian models derived from induced pluripotent stem cells and related methods
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
JP6219923B2 (ja) 2012-03-28 2017-10-25 アムジェン インコーポレイテッド Ｄｒ５受容体アゴニストの組み合わせ
CA2871468C (en) 2012-04-23 2021-09-21 Nrl Pharma, Inc. Lactoferrin fusion protein and method for preparation thereof
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US20150133383A1 (en) 2012-05-11 2015-05-14 Prorec Bio Ab Method for diagnosis and treatment of prolactin associated disorders
AU2013263349B2 (en) 2012-05-17 2016-09-08 Extend Biosciences, Inc Carriers for improved drug delivery
NZ703724A (en) 2012-06-11 2017-06-30 Amgen Inc Dual receptor antagonistic antigen-binding proteins and uses thereof
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
UY34905A (es) 2012-07-12 2014-01-31 Abbvie Inc Proteínas de unión a il-1
EP2875046B2 (en) 2012-07-19 2025-04-30 Amgen Inc. Human btnl3 proteins, nucleic acids, and antibodies and uses thereof
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
BR112015008663B1 (pt) * 2012-10-17 2021-01-12 CSL Behring Lengnau AG Uso de uma quantidade eficaz de uma proteína polimérica compreendendo seis unidades demonômero de polipeptídeo
AU2013334790A1 (en) 2012-10-23 2015-04-30 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
TW202037609A (zh) 2012-11-01 2020-10-16 美商艾伯維有限公司 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
WO2014073842A1 (en) 2012-11-06 2014-05-15 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
US9867841B2 (en) 2012-12-07 2018-01-16 Glycomimetics, Inc. Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
US20160067347A1 (en) * 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
US10632179B2 (en) * 2013-01-11 2020-04-28 Case Western Reserve University Methods and compositions for treating cancer
KR102073748B1 (ko) 2013-01-31 2020-02-05 한미약품 주식회사 재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법
AU2014212014A1 (en) 2013-02-01 2015-08-27 Amgen Inc. Administration of an anti-activin-A compound to a subject
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
DK2963056T3 (da) * 2013-02-26 2020-02-17 Hanmi Pharm Ind Co Ltd Insulinanalog og anvendelse deraf
CN105188750A (zh) 2013-03-08 2015-12-23 德国杰特贝林生物制品有限公司 治疗和预防远端缺血-再灌注损伤
WO2014136814A1 (ja) * 2013-03-08 2014-09-12 大鵬薬品工業株式会社 新規ｃｔｌエピトープ５連結ペプチド
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
CN105188733B (zh) * 2013-03-13 2020-05-08 建新公司 包含pdgf和vegf结合部分的融合蛋白及其使用方法
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
WO2014144325A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
JP6649250B2 (ja) * 2013-05-21 2020-02-19 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたヘム結合性構成物およびその使用
US10183988B2 (en) 2013-06-07 2019-01-22 Duke University Anti-Complement factor H antibodies
CA2916399C (en) 2013-06-28 2022-08-02 Marc Nolte Combination therapy using a factor xii inhibitor and a c1-inhibitor
CA2916259C (en) 2013-06-28 2024-02-20 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
HK1218252A1 (zh) 2013-07-25 2017-02-10 Novartis Ag 合成apelin多肽之生物结合物
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
EP3046933B1 (en) * 2013-09-18 2019-02-27 BCN Peptides, S.A. Cortistatin analogues for the treatment of inflammatory and/or immune diseases
WO2015057820A2 (en) * 2013-10-15 2015-04-23 Roberts S Kenny Peptide constructs and well-defined aggregates thereof
EP3057605A1 (en) 2013-10-18 2016-08-24 Novartis AG Methods of treating diabetes and related disorders
PT3061771T (pt) * 2013-10-21 2020-05-06 Taiho Pharmaceutical Co Ltd Novo péptido unido a quatro epitopos ctl
HRP20192080T1 (hr) 2013-10-31 2020-02-07 Resolve Therapeutics, Llc Terapeutske fuzije nukleaza-albumine i postupci
US10513546B2 (en) 2013-12-18 2019-12-24 President And Fellows Of Harvard College CRP capture/detection of gram positive bacteria
WO2015104711A1 (en) 2014-01-09 2015-07-16 Hadasit Medical Research Services And Development Ltd. Improved cell compositions and methods for cancer therapy
US20150291689A1 (en) 2014-03-09 2015-10-15 Abbvie, Inc. Compositions and Methods for Treating Rheumatoid Arthritis
JP6685924B2 (ja) * 2014-04-11 2020-04-22 メディミューン，エルエルシー システイン操作抗体を含むコンジュゲート化合物
BR122021009041B1 (pt) 2014-05-06 2022-11-29 Genentech, Inc Métodos para a preparação de uma proteína heteromultimérica
US20160002326A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Compositions and methods for treating rheumatoid arthritis
WO2015191781A2 (en) 2014-06-10 2015-12-17 Amgen Inc. Apelin polypeptides
JP7109160B2 (ja) 2014-06-18 2022-07-29 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 神経外傷性障害において第ｘｉｉ因子インヒビターを使用する療法
BR112016030950A2 (pt) 2014-07-02 2018-03-27 Csl Ltd polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.
US10526391B2 (en) 2014-07-22 2020-01-07 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
WO2016044224A1 (en) 2014-09-15 2016-03-24 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
MX377591B (es) 2014-10-15 2025-03-10 Amgen Inc Elementos promotores y reguladores para mejorar la expresión de genes heterólogos en células hospederas.
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065181A1 (en) 2014-10-23 2016-04-28 Amgen Inc. Reducing viscosity of pharmaceutical formulations
WO2016069889A1 (en) 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
AU2015371172B2 (en) * 2014-12-22 2021-05-13 Lanthiopep B.V. Novel methods for displaying cyclic peptides on bacteriophage particles
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
TW201639596A (zh) 2015-01-24 2016-11-16 艾伯維有限公司 用於治療牛皮癬性關節炎之組合物及方法
JP6942051B2 (ja) * 2015-01-30 2021-09-29 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション 二量体のコラーゲンハイブリダイゼーションペプチドと使用方法
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10711067B2 (en) 2015-03-03 2020-07-14 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
US10472408B2 (en) * 2015-03-05 2019-11-12 Peter Und Traudl Engelhorn-Stiftung Zur Förderung Der Lebenswissenschaften Fusion proteins comprising partial tetraspanin sequences and a system thereof for presenting peptides on the cell surface
EP3281010B1 (en) 2015-04-10 2020-12-30 The Regents of The University of California Methods of determining patient populations amenable to immunomodulatory treatment of cancer
WO2016176427A1 (en) 2015-04-30 2016-11-03 Amgen Inc. Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane
US10806804B2 (en) 2015-05-06 2020-10-20 Washington University Compounds having RD targeting motifs and methods of use thereof
JP6651548B2 (ja) 2015-05-22 2020-02-19 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 改変フォン・ヴィルブランド因子を製造するための方法
EP3297656B1 (en) 2015-05-22 2020-01-08 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2016209972A1 (en) 2015-06-26 2016-12-29 Amgen Inc. Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
EP3331549B1 (en) 2015-08-06 2020-12-23 President and Fellows of Harvard College Improved microbe-binding molecules and uses thereof
CA2998174A1 (en) 2015-09-15 2017-03-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
EP3356415B1 (en) 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
US20180280474A1 (en) 2015-10-01 2018-10-04 Amgen Inc. Treatment of bile acid disorders
WO2017055404A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
US10975131B2 (en) 2015-10-27 2021-04-13 University Of Massachusetts Factor H-Fc immunotheraphy
KR101826792B1 (ko) * 2015-10-29 2018-02-09 주식회사 와이바이오로직스 Dlk1의 세포 외 수용성 도메인을 유효성분으로 포함하는 지방간 또는 인슐린 저항성 증후군 예방 및 치료용 조성물
BR112018012237A2 (pt) * 2015-12-15 2018-12-04 Sarepta Therapeutics Inc conjugados oligonucleotídeos-peptídeos
US10822408B2 (en) 2015-12-15 2020-11-03 Amgen Inc. PACAP antibodies and uses thereof
EP3390378B1 (en) 2015-12-17 2022-03-30 AlonBio Ltd. Small molecules against cancer
AU2016371466B2 (en) 2015-12-17 2020-04-09 Alonbio Ltd Small Molecules for Inhibiting Chemokine Activity and/or Cancer Cells Growth
EP3184149A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Soluble glycoprotein v for treating thrombotic diseases
DK3400002T3 (da) 2016-01-07 2022-04-11 CSL Behring Lengnau AG Muteret, trunkeret von willebrand faktor
RU2018128613A (ru) 2016-01-07 2020-02-07 Цсл Беринг Ленгнау Аг Мутированный фактор фон виллебранда
US11174321B2 (en) 2016-04-06 2021-11-16 Csl Limited Method of treating atherosclerosis
KR101975743B1 (ko) * 2016-04-07 2019-05-09 한양대학교 에리카산학협력단 신혈관 생성 억제를 위한 혈관내피성장인자 수용체 타겟팅 펩타이드-엘라스틴 융합 폴리펩타이드 및 자가조립 나노구조체
EP3444264A4 (en) * 2016-04-14 2020-03-18 TAO Health Life Pharma Co., Ltd. Peptide for inhibiting binding of amylospheroids (aspd), and evaluation and screening method
JP2019515677A (ja) 2016-04-26 2019-06-13 アール．ピー．シェーラー テクノロジーズ エルエルシー 抗体複合体ならびにそれを作製および使用する方法
AU2017279550A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
CA3029627A1 (en) 2016-07-01 2018-01-04 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
KR102579850B1 (ko) 2016-07-22 2023-09-18 암젠 인크 Fc-함유 단백질의 정제 방법
WO2018022917A1 (en) * 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Disulfide-rich peptide libraries and methods of use thereof
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CN106317226B (zh) 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
EP3522918A1 (en) 2016-10-06 2019-08-14 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
WO2018079702A1 (ja) 2016-10-28 2018-05-03 株式会社Ｎｒｌファーマ ラクトフェリン／アルブミン融合タンパク質及びその製造方法
SG11201903954WA (en) 2016-11-11 2019-05-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
US11814421B2 (en) 2016-11-11 2023-11-14 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia
EP3544628A4 (en) 2016-11-23 2020-11-18 Immunoah Therapeutics, Inc. 4-1BB BINDING PROTEINS AND THEIR USES
EP3496742A4 (en) * 2016-12-01 2020-04-08 University Of South Florida PEPTICORPS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING EAR FIBRILLATION
WO2018132768A1 (en) 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
KR102629006B1 (ko) 2017-03-23 2024-01-25 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
MY201482A (en) 2017-04-03 2024-02-26 Hoffmann La Roche Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
EP4516809A3 (en) 2017-04-05 2025-09-03 F. Hoffmann-La Roche AG Bispecific antibodies specifically binding to pd1 and lag3
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
ES2966835T3 (es) 2017-06-22 2024-04-24 CSL Behring Lengnau AG Modulación de la inmunogenicidad del FVIII por VWF truncado
EP3655439A1 (en) 2017-07-20 2020-05-27 Aptevo Research and Development LLC Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
AU2018306329B8 (en) 2017-07-26 2025-02-20 Janssen Pharmaceutica Nv Methods of protecting vascular integrity induced by targeted radiation therapy
WO2019028012A2 (en) 2017-07-31 2019-02-07 Dana-Farber Cancer Institute, Inc. METHODS OF USING PEMBROLIZUMAB AND TREBANANIB
LT3661562T (lt) 2017-08-04 2024-10-25 Amgen Inc. Cys-mab konjugavimo būdas
CN111164104A (zh) 2017-08-09 2020-05-15 麻省理工学院 白蛋白结合肽缀合物及其方法
EP3684811A2 (en) 2017-08-17 2020-07-29 Massachusetts Institute of Technology Multiple specificity binders of cxc chemokines and uses thereof
EP3668985B1 (en) 2017-08-17 2021-06-16 Just-Evotec Biologics, Inc. Method of purifying glycosylated protein from host cell galectins and other contaminants
CA3073537A1 (en) 2017-08-22 2019-02-28 Sanabio, Llc Soluble interferon receptors and uses thereof
JP2021506851A (ja) 2017-12-19 2021-02-22 マサチューセッツ インスティテュート オブ テクノロジー 抗原−アジュバントカップリング試薬および使用の方法
EP3777894A4 (en) * 2018-03-30 2022-04-06 Hanmi Pharm. Co., Ltd. ANTI-BRAIN DIRECTIONAL LONG-ACTING PROTEIN CONJUGATE, METHOD OF MANUFACTURE THEREOF AND COMPOSITION THEREOF
TWI805792B (zh) 2018-06-29 2023-06-21 日商大鵬藥品工業股份有限公司 抗腫瘤劑及其評估方法
MX2021004510A (es) 2018-10-23 2021-06-08 Amgen Inc Calibracion automatica y mantenimiento automatico de modelos espectroscopicos de raman para predicciones en tiempo real.
US20210395751A1 (en) 2018-10-31 2021-12-23 The University Of Sydney Compositions and methods for treating viral infections
WO2020142740A1 (en) 2019-01-04 2020-07-09 Resolve Therapeutics, Llc Treatment of sjogren's disease with nuclease fusion proteins
AU2020207203A1 (en) * 2019-01-07 2021-08-19 Cenna Biosciences Inc. Novel peptides and uses thereof
EP3914286B1 (en) 2019-01-25 2025-05-07 Janssen Pharmaceutica NV Methods of mitigating toxic effects of vesicants and caustic gas
MX2021008943A (es) 2019-01-25 2021-11-04 Janssen Pharmaceutica Nv Metodos para mitigar la lesion hepatica y promover la hipertrofia hepatica, la regeneracion e injerto celular en conjunto con tratamientos de radiacion y/o radiomimeticos.
WO2020154637A1 (en) 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
JP2022520793A (ja) 2019-02-15 2022-04-01 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 自動バイオ製造システム、施設、及びプロセス
US20230051872A1 (en) 2019-03-22 2023-02-16 Reflexion Pharmaceuticals, Inc. Multivalent D-Peptidic Compounds for Target Proteins
KR20220044612A (ko) 2019-03-22 2022-04-08 리플렉시온 파마슈티컬스, 인크. Vegf에 대한 d-펩티드성 화합물
ES3014809T3 (en) 2019-05-15 2025-04-25 Alonbio Ltd Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death
KR20220009984A (ko) 2019-05-17 2022-01-25 유니베르시태트 취리히 출혈성 뇌졸중 후 2차 신경학적 이상 반응을 치료하는데 사용하기 위한 합토글로빈
JP7500619B2 (ja) 2019-05-30 2024-06-17 アムジエン・インコーポレーテツド 抗体の二量体化を促進するためのヒンジ領域の操作
IL267614A (en) 2019-06-24 2019-09-26 Lotem Michal Nucleic acids to modulate SLAMF6 isoforms
WO2020263399A1 (en) 2019-06-26 2020-12-30 Massachusetts Institute Of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
US20220363770A1 (en) 2019-06-28 2022-11-17 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
US20220242962A1 (en) 2019-08-12 2022-08-04 Aptevo Research And Development Llc 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
ES3040852T3 (en) 2019-11-08 2025-11-05 Amgen Inc Engineering charge pair mutations for pairing of hetero-igg molecules
US20220348637A1 (en) 2019-11-11 2022-11-03 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
JP7835441B2 (ja) 2019-12-06 2026-03-25 トゥルーバインディング，インコーポレイテッド Ｇａｌ３とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法
US11712482B2 (en) 2019-12-13 2023-08-01 Washington University Near infrared fluorescent dyes, formulations and related methods
WO2021145946A1 (en) * 2020-01-13 2021-07-22 Invenra Inc. Multispecific treg binding molecules
WO2021146328A1 (en) 2020-01-13 2021-07-22 Aptevo Research And Development Llc Formulations for protein therapeutics
WO2021158469A1 (en) 2020-02-03 2021-08-12 Amgen Inc. Multivariate bracketing approach for sterile filter validation
JP2023515825A (ja) * 2020-02-28 2023-04-14 ノースウェスタン ユニバーシティ 血管疾患を治療するためのアンジオポエチン模倣物およびｔｉｅ２アゴニストとしての、ｃ４結合タンパク質ｃ末端セグメントとアンジオポエチン－１フィブリノゲン様ドメインとの間のキメラ融合
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
CA3165342A1 (en) 2020-06-29 2022-01-06 James Arthur Posada Treatment of sjogren's syndrome with nuclease fusion proteins
US20230322955A1 (en) 2020-08-20 2023-10-12 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
US20230374162A1 (en) 2020-10-07 2023-11-23 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
WO2022103773A1 (en) 2020-11-10 2022-05-19 Amgen Inc. Novel linkers of multispecific antigen binding domains
WO2022109124A1 (en) 2020-11-20 2022-05-27 Csl Behring Gmbh Method for treating antibody-mediated rejection
IL303328A (en) 2020-12-01 2023-07-01 Aptevo Res & Development Llc Heterodimeric psma and cd3-binding bispecific antibodies
ES3040791T3 (en) 2020-12-18 2025-11-05 Richter Gedeon Nyrt Methods for the purification of refolded fc-peptide fusion protein
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2022162218A1 (en) 2021-02-01 2022-08-04 Csl Behring Ag Method of treating or preventing an adverse secondary neurological outcome following a haemorrhagic stroke
MX2023012324A (es) 2021-04-20 2023-10-30 Amgen Inc Distribucion de carga equilibrada en una direccion electrostatica del emparejamiento de cadenas en el conjunto de moleculas de igg multiespecificas y monovalentes.
KR20240005075A (ko) 2021-05-07 2024-01-11 체에스엘 베링 아게 재조합 합토글로빈 (hp) 베타 쇄를 생산하기 위한 발현 시스템
EP4341291A1 (en) 2021-05-21 2024-03-27 Aptevo Research and Development LLC Dosing regimens for protein therapeutics
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
JP2024526764A (ja) 2021-07-13 2024-07-19 トゥルーバインディング，インコーポレイテッド タンパク質凝集を防止する方法
WO2023056444A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica N.V. Methods of increasing progenitor cell production
MX2024004550A (es) 2021-10-14 2024-04-29 Teneobio Inc Proteinas de union a la mesotelina y usos de las mismas.
JP2025500732A (ja) 2021-10-27 2025-01-15 アムジエン・インコーポレーテツド 分光法を使用して薬剤を監視するための深層学習ベースの予測
CN118524852A (zh) 2021-11-09 2024-08-20 真和制药有限公司 治疗或抑制心血管疾病的方法
WO2023173084A1 (en) 2022-03-11 2023-09-14 University Of Rochester Cyclopeptibodies and uses thereof
MX2024010846A (es) 2022-03-24 2024-09-11 Richter Gedeon Nyrt Metodo para la preparacion de biofarmacos.
US20260035478A1 (en) 2022-07-27 2026-02-05 Teneobio, Inc. Mesothelin binding proteins and uses thereof
JP2025530774A (ja) 2022-09-02 2025-09-17 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 過剰勃起応答または勃起不全の処置または予防に使用するハプトグロビン
KR20250075704A (ko) 2022-09-30 2025-05-28 익스텐드 바이오사이언시즈, 인크. 장기-지속형 부갑상선 호르몬
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure
CN120584137A (zh) 2023-01-06 2025-09-02 阿帕特夫研究和发展有限公司 双特异性pd-l1和cd40结合分子以及其用途
AU2024226156A1 (en) 2023-02-21 2025-08-28 Teneobio, Inc. C-kit binding proteins, chimeric antigen receptors, and uses thereof
EP4724490A2 (en) 2023-06-12 2026-04-15 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins
WO2025037108A2 (en) 2023-08-15 2025-02-20 Board Of Trustees Of The Leland Stanford Junior University Modified thrombopoietin
WO2025147696A1 (en) 2024-01-05 2025-07-10 Resolve Therapeutics, Llc Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents
CN117986346B (zh) * 2024-04-07 2024-07-26 中国人民解放军军事科学院军事医学研究院 一种tpo模拟肽及其应用
WO2025257801A1 (en) 2024-06-13 2025-12-18 CSL Innovation Pty Ltd Heme-binding protein for the treatment of ischemia-reperfusion injury (iri)

Family Cites Families (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) * 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) * 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) * 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4195128A (en) * 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) * 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) * 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) * 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
IN150740B (https=) 1978-11-24 1982-12-04 Hoffmann La Roche
US4289872A (en) * 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4760067A (en) 1979-08-15 1988-07-26 Merck & Co., Inc. Allylsulfoxide enzyme inhibitors
EP0040506B1 (en) 1980-05-21 1986-08-20 Teijin Limited Reactive polymer and process for the preparation thereof
US4560649A (en) 1981-10-15 1985-12-24 Cornell Research Foundation Assaying for hLH or hCG with immobilized hormone receptors
JPH0751511B2 (ja) 1982-03-15 1995-06-05 味の素株式会社 インターロイキン２を含有してなる癌治療剤
EP0092918B1 (en) 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
US4587046A (en) 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4966888A (en) 1985-07-08 1990-10-30 Cornell Research Foundation, Inc. hCG-hLH receptor and hCG-hLH receptor-hCG complex as antigens, antibodies thereto and contraceptive vaccine
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4522750A (en) 1984-02-21 1985-06-11 Eli Lilly And Company Cytotoxic compositions of transferrin coupled to vinca alkaloids
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
SE470099B (sv) 1984-05-17 1993-11-08 Jerker Porath Sulfonaktiverade tioeteradsorbenter för separation av t ex protein
US4578335A (en) 1984-05-21 1986-03-25 Immunex Corporation Interleukin 2 receptor
US4670563A (en) 1984-06-20 1987-06-02 Sanofi Imidazolides as intermediates for the synthesis of cytotoxic conjugates
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4675285A (en) 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
SE454885B (sv) 1984-10-19 1988-06-06 Exploaterings Ab Tbf Polymerbelagda partiklar med immobiliserade metalljoner pa sin yta jemte forfarande for framstellning derav
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JP2524586B2 (ja) 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JPS62185029A (ja) 1986-02-07 1987-08-13 Ajinomoto Co Inc 修飾インタ−ロイキン−２
US5985599A (en) 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
CA1283046C (en) 1986-05-29 1991-04-16 Nandini Katre Tumor necrosis factor formulation
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IN165717B (https=) 1986-08-07 1989-12-23 Battelle Memorial Institute
AU610083B2 (en) * 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US4931544A (en) 1986-09-04 1990-06-05 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
IL80005A (en) 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
US4965271A (en) 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5359032A (en) 1987-08-26 1994-10-25 Biogen Inc. Interkeukin-1 inhibitor
US5512544A (en) 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
IL90339A (en) 1989-05-18 1996-10-16 Yeda Res & Dev Anti-cytotoxic protein and its purification
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5153265A (en) 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
DE68926888T2 (de) 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
GB8806339D0 (en) 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
IL89790A (en) 1988-04-01 2002-05-23 Johns Hopking University Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US5214131A (en) 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
KR0148009B1 (ko) 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
JPH0240399A (ja) 1988-07-27 1990-02-09 Takeda Chem Ind Ltd 線維芽細胞増殖因子ムテインの複合体あるいは組成物
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
US5811261A (en) 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
GB8824592D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Purification process
GB8824869D0 (en) 1988-10-24 1988-11-30 Stevenson G T Synthetic antibody
US5681566A (en) 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
WO1990005534A1 (en) 1988-11-23 1990-05-31 Genentech, Inc. Polypeptide derivatives
WO1990006774A1 (en) 1988-12-22 1990-06-28 Xoma Corporation Hindered linking agents and methods
WO1990006953A2 (en) 1988-12-22 1990-06-28 Genentech, Inc. Method for preparing water soluble polypeptides
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5098833A (en) 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
US5216131A (en) 1989-02-23 1993-06-01 Genentech, Inc. Lymphocyte homing receptors
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
EP0386289A1 (en) 1989-03-07 1990-09-12 Taniguchi, Tadatsugu, Dr. Recombinant interleukin-2 receptor
CA2011450C (en) 1989-03-07 2002-06-04 Tadatsugu Taniguchi Recombinant b-chain of the il-2 receptor
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DK0393438T3 (da) 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
AU636608B2 (en) 1989-05-18 1993-05-06 Yeda Research And Development Co. Ltd. Tumor necrosis factor binding protein II, it's purification and antibodies thereto
US5627262A (en) 1989-07-05 1997-05-06 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
WO1991003553A1 (en) 1989-09-05 1991-03-21 Immunex Corporation TUMOR NECROSIS FACTOR-α AND -β RECEPTORS
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5234903A (en) 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
EP0502956B1 (en) 1989-11-29 1997-04-23 Amgen Boulder Inc. Production of recombinant human interleukin-1 inhibitor
AU642938B2 (en) 1989-12-13 1993-11-04 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein 1 (TBP-1)
DE59105962D1 (de) † 1990-01-23 1995-08-17 Merck Patent Gmbh Flüssigkristallines medium.
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US5171264A (en) 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
US5349053A (en) † 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB2246569A (en) 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
WO1992001002A1 (en) 1990-07-11 1992-01-23 Teijin Limited Tumor necrosis factor activity inhibitor and production thereof
ES2183851T3 (es) 1990-07-17 2003-04-01 Univ Oklahoma Ligando de gmp-140.
GB9015908D0 (en) 1990-07-19 1990-09-05 Celltech Ltd Multivalent immunoglobulin
AU657483B2 (en) 1990-07-20 1995-03-16 Pharmacia Ab Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures
DE69120821T2 (de) 1990-08-31 1997-01-23 The Regents Of The University Of Minnesota, Minneapolis, Minn. Polyethylenglykol-Derivate für Festphasenanwendungen
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ES2145744T5 (es) 1991-01-18 2008-02-01 Amgen Inc. Procedimientos para tratar las enfermedades inducidas por el factor de necrosis tumoral.
CA2100671C (en) 1991-02-27 1999-02-02 James S. Huston Serine rich peptide linkers
JP3507486B2 (ja) * 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
JPH06506217A (ja) 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
US6139843A (en) 1991-04-02 2000-10-31 Albert Einstein College Of Medicine Of Yeshiva University Peptide compositions for the treatment of HIV
DK0594772T3 (https=) 1991-07-04 1997-02-24 Immunodex K S
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5376367A (en) 1991-11-22 1994-12-27 Immunex Corporation Fusion proteins comprising MGF and IL-3
US5569779A (en) 1991-12-23 1996-10-29 Albemarle Corporation Polyfunctional michael addition products
WO1993021259A1 (en) 1992-04-14 1993-10-28 Cornell Research Foundation Inc. Dendritic based macromolecules and method of production
CA2118508A1 (en) † 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
ATE311895T1 (de) 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
AU677789B2 (en) 1992-07-02 1997-05-08 Collagen Corporation Biocompatible polymer conjugates
AU5098393A (en) * 1992-08-14 1994-03-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant toxin with increased half-life
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
AU670125B2 (en) * 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5844094A (en) 1992-09-25 1998-12-01 Commonwealth Scientific And Industrial Research Organization Target binding polypeptide
NZ247231A (en) * 1993-03-23 1994-10-26 Holyoake Ind Ltd Diffuser for air conditioning system; outlet air direction thermostatically controlled
EP0622394A1 (en) 1993-04-30 1994-11-02 S.A. Laboratoires S.M.B. Reversible modification of sulfur-containing molecules with polyalkylene glycol derivatives and their use
US5958409A (en) 1993-07-30 1999-09-28 Kennedy Institute Of Rheumatology Method for treating multiple sclerosis
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5998172A (en) † 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
GB2285446B (en) 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
US5786331A (en) 1994-02-02 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5608035A (en) 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5880096A (en) 1994-02-02 1999-03-09 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
NZ271230A (en) 1994-02-14 1998-03-25 Zymogenetics Inc Hematopoietic proteins, production and use
GEP20002180B (en) 1994-03-31 2000-07-25 Amgen Inc Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation
CA2189657C (fr) † 1994-05-06 2002-03-12 Florence Faure Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype
US6184205B1 (en) † 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
IL111196A0 (en) 1994-10-07 1994-12-29 Yeda Res & Dev Peptides and pharmaceutical compositions comprising them
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU693478B2 (en) 1994-11-10 1998-07-02 Metabolic Pharmaceuticals Limited Treatment of obesity
EP0796335A1 (en) 1994-12-07 1997-09-24 Bionebraska, Inc. Production of peptides using recombinant fusion protein constructs
DE69534265T2 (de) 1994-12-12 2006-05-04 Beth Israel Deaconess Medical Center, Inc., Boston Chimäre zytokine und ihre verwendung
TW313568B (https=) 1994-12-20 1997-08-21 Hoffmann La Roche
WO1996023899A1 (en) 1995-02-01 1996-08-08 University Of Massachusetts Medical Center Methods of selecting a random peptide that binds to a target protein
IL113159A0 (en) 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) * 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US6083913A (en) 1995-06-07 2000-07-04 Glaxo Wellcome Inc. Peptides and compounds that bind to a thrombopoietin receptor
AU6046696A (en) 1995-06-07 1996-12-30 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
IL118524A (en) 1995-06-19 2004-02-19 Akzo Nobel Nv Peptides and pharmaceutical preparations containing them useful in the treatment of peptide tolerance
US5955574A (en) † 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
WO1997008553A1 (en) 1995-08-22 1997-03-06 The Regents Of The University Of California Targeting of proteins to the cell wall of gram-positive bacteria
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
SK288144B6 (sk) 1996-02-09 2013-12-02 Amgen, Inc. Pharmaceutical composition and its use for treating inflammatory diseases
IL117223A0 (en) 1996-02-22 1996-06-18 Yeda Res & Dev Antipathogenic polypeptides and compositions comprising them
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US5798246A (en) 1996-03-25 1998-08-25 Incyte Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterase
AU2597897A (en) 1996-03-28 1997-10-17 Brigham And Women's Hospital Peptide ligands of the urokinase receptor
IL118003A0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
WO1997043316A1 (en) † 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
AU2978697A (en) 1996-06-07 1998-01-05 Takeda Chemical Industries Ltd. Novel peptide, process for the production of the same, and use of the same
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
CA2265484C (en) 1996-09-10 2008-12-02 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same
US5932546A (en) 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
DK0934526T3 (da) 1996-10-08 2003-05-05 Bisys B V U Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål
US5958703A (en) * 1996-12-03 1999-09-28 Glaxo Group Limited Use of modified tethers in screening compound libraries
ES2312179T3 (es) 1996-12-06 2009-02-16 Amgen Inc. Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1.
CA2275183A1 (en) 1996-12-20 1998-07-02 Amgen Inc. Ob fusion protein compositions and methods
KR19980066046A (ko) 1997-01-18 1998-10-15 정용훈 고역가의 CTLA4-Ig 융합단백질
US5955431A (en) 1997-02-05 1999-09-21 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors
ATE223229T1 (de) 1997-04-17 2002-09-15 Amgen Inc Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
US6265535B1 (en) 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
JP2002504818A (ja) 1997-06-06 2002-02-12 リジェネロン ファーマシューティカルズ，インコーポレイテッド リガンドファミリーのｎｔｎ−２メンバー
AU741546B2 (en) 1997-07-24 2001-12-06 Perseptive Biosystems, Inc. Conjugates of transporter peptides and nucleic acid analogs, and their use
US6238667B1 (en) 1997-09-19 2001-05-29 Heinz Kohler Method of affinity cross-linking biologically active immunogenic peptides to antibodies
CA2306246A1 (en) 1997-10-06 1999-04-15 Millennium Pharmaceuticals, Inc. Signal peptide containing proteins and uses therefor
CN1138472C (zh) 1997-10-10 2004-02-18 西托维亚公司 二肽型编程性细胞死亡抑制剂及其用途
ATE235513T1 (de) 1997-11-07 2003-04-15 Conjuchem Inc Opioid-konjugate mit endogenen trägerproteinen
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
MEP42108A (en) 1998-10-23 2011-02-10 Kiren Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
ATE293989T1 (de) * 1998-11-20 2005-05-15 Genentech Inc Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
WO2000047740A2 (en) * 1999-02-12 2000-08-17 Amgen Inc. Tnf-related proteins
WO2000059530A1 (en) 1999-04-02 2000-10-12 Immunex Corporation Use of soluble tumor necrosis factor receptor for treatment heart failure
IL147270A0 (en) † 1999-07-02 2002-08-14 Genentech Inc Fusion peptides comprising a peptide ligand domain and a multimerization domain
AU779612C (en) † 1999-07-02 2005-12-15 Genentech Inc. Peptide compounds that bind HER2
EP1254227A2 (en) * 2000-02-11 2002-11-06 Amgen Inc. Fusion receptor from tnf family
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7241733B2 (en) 2002-06-28 2007-07-10 Centocor, Inc. Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
CA2490409A1 (en) 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
US6919426B2 (en) * 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
EP1778264A2 (en) * 2004-06-25 2007-05-02 Licentia, Ltd. Tie receptor and tie ligand materials and methods for modulating female fertility
ZA200705695B (en) * 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof

Also Published As

Publication number Publication date
ZA200102753B (en) 2002-06-11
KR100753303B1 (ko) 2007-08-29
KR20070050977A (ko) 2007-05-16
EA200100464A1 (ru) 2002-10-31
CN100384880C (zh) 2008-04-30
PT1144454E (pt) 2008-02-08
SK287037B6 (sk) 2009-10-07
AU767725B2 (en) 2003-11-20
CN1746190A (zh) 2006-03-15
CN1781946A (zh) 2006-06-07
BG65721B1 (bg) 2009-08-31
US7186810B2 (en) 2007-03-06
NO20011963D0 (no) 2001-04-20
PL366080A1 (en) 2005-01-24
CN1908014A (zh) 2007-02-07
US20040044188A1 (en) 2004-03-04
SK5252001A3 (en) 2002-12-03
KR20010099706A (ko) 2001-11-09
JP2007084555A (ja) 2007-04-05
CA2347131A1 (en) 2000-05-04
US20040071712A1 (en) 2004-04-15
NO20011963L (no) 2001-06-21
HK1042097B (en) 2008-04-03
ES2299278T3 (es) 2008-05-16
AU1232200A (en) 2000-05-15
ATE380828T1 (de) 2007-12-15
NO331733B1 (no) 2012-03-12
JP2007084557A (ja) 2007-04-05
US20070049532A1 (en) 2007-03-01
AU767725C (en) 2000-05-15
EP1144454A2 (en) 2001-10-17
US20040057953A1 (en) 2004-03-25
CA2347131C (en) 2012-11-27
US7189827B2 (en) 2007-03-13
HUP0203506A3 (en) 2012-09-28
CN1781947A (zh) 2006-06-07
JP2007084558A (ja) 2007-04-05
DE69937752T2 (de) 2008-12-24
IL142365A (en) 2013-02-28
SI1144454T2 (sl) 2013-04-30
US6660843B1 (en) 2003-12-09
CN1746189A (zh) 2006-03-15
AU2004200687A1 (en) 2004-03-18
CN1781945A (zh) 2006-06-07
US20040053845A1 (en) 2004-03-18
NZ528882A (en) 2005-06-24
CN1331701A (zh) 2002-01-16
SI1144454T1 (sl) 2008-04-30
CN1310948C (zh) 2007-04-18
WO2000024782A2 (en) 2000-05-04
AU2004200690B2 (en) 2007-05-10
DE69937752D1 (de) 2008-01-24
YU25901A (sh) 2005-07-19
AU2004200687B2 (en) 2007-05-10
AU2004200690A1 (en) 2004-03-18
US7169905B2 (en) 2007-01-30
CN1721447A (zh) 2006-01-18
EP1144454B1 (en) 2007-12-12
EP1144454B2 (en) 2012-12-12
EA005404B1 (ru) 2005-02-24
JP2007089586A (ja) 2007-04-12
AU2004200690C1 (en) 2009-04-09
CY1107881T1 (el) 2013-06-19
DK1144454T4 (da) 2013-01-14
HU229485B1 (en) 2014-01-28
JP2007091746A (ja) 2007-04-12
HK1090932A1 (en) 2007-01-05
IL142365A0 (en) 2002-03-10
JP2003512011A (ja) 2003-04-02
CZ304242B6 (cs) 2014-01-22
BG105461A (en) 2003-04-30
US7166707B2 (en) 2007-01-23
JP2007084556A (ja) 2007-04-05
HK1042097A1 (en) 2002-08-02
WO2000024782A3 (en) 2002-06-06
NZ510888A (en) 2004-01-30
BR9914708A (pt) 2002-07-16
ES2299278T5 (es) 2013-04-03
KR100753305B1 (ko) 2007-08-29
JP2007091747A (ja) 2007-04-12
KR100753304B1 (ko) 2007-08-29
PL211164B1 (pl) 2012-04-30
KR20070050978A (ko) 2007-05-16
HUP0203506A2 (hu) 2003-02-28
DK1144454T3 (da) 2008-05-05
CN100384879C (zh) 2008-04-30
DE69937752T3 (de) 2013-02-28
JP2007105044A (ja) 2007-04-26
MXPA01003873A (es) 2003-10-14
US20040087778A1 (en) 2004-05-06
AU2004200687C1 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
RS51852B (sr) Modifikovani peptidi kao terapeutski agensi
TWI250988B (en) Thrombopoietic compounds
JP2003533187A (ja) 治療薬としてのＦｃドメインを含む修飾ペプチド
KR20040066099A (ko) 혈소판신생 활성을 갖는 펩티드 및 관련 화합물
US20110071077A1 (en) Thrombopoietic Compounds
AU2004200691C1 (en) Modified peptides as therapeutic agents
HK1090932B (en) Modified peptides as therapeutic agents